Eli Lilly and Company (NYSE:LLY) Upgraded at Redburn Atlantic

Eli Lilly and Company (NYSE:LLY) was upgraded by Redburn Atlantic to a “hold” rating in a research note issued to investors on Monday, Zacks.com reports.

Several other research analysts also recently issued reports on the stock. Citigroup boosted their price objective on shares of Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the stock a “buy” rating in a report on Friday, October 25th. Sanford C. Bernstein started coverage on Eli Lilly and Company in a research note on Thursday, October 17th. They set an “outperform” rating and a $1,100.00 price target on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $885.00 price objective on shares of Eli Lilly and Company in a research report on Monday, September 16th. Morgan Stanley reissued an “overweight” rating and set a $1,106.00 price objective on shares of Eli Lilly and Company in a report on Tuesday, August 27th. Finally, Bank of America cut their target price on Eli Lilly and Company from $1,150.00 to $1,100.00 and set a “buy” rating for the company in a research note on Thursday, October 31st. Four investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,008.41.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $806.60 on Monday. The company has a market cap of $765.72 billion, a price-to-earnings ratio of 87.20, a PEG ratio of 3.09 and a beta of 0.43. The business has a 50 day moving average price of $905.20 and a 200 day moving average price of $867.96. The company has a quick ratio of 0.97, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. Eli Lilly and Company has a twelve month low of $561.65 and a twelve month high of $972.53.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing the consensus estimate of $1.52 by ($0.34). The business had revenue of $11.44 billion during the quarter, compared to the consensus estimate of $12.09 billion. Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The firm’s revenue was up 20.4% compared to the same quarter last year. During the same period in the prior year, the company posted $0.10 earnings per share. Research analysts predict that Eli Lilly and Company will post 13.23 earnings per share for the current year.

Hedge Funds Weigh In On Eli Lilly and Company

A number of institutional investors and hedge funds have recently bought and sold shares of the business. M&G Plc acquired a new position in Eli Lilly and Company during the 1st quarter worth about $8,896,000. Virtu Financial LLC bought a new stake in shares of Eli Lilly and Company during the first quarter valued at approximately $2,138,000. China Universal Asset Management Co. Ltd. increased its holdings in shares of Eli Lilly and Company by 19.6% in the first quarter. China Universal Asset Management Co. Ltd. now owns 9,897 shares of the company’s stock valued at $7,699,000 after purchasing an additional 1,620 shares in the last quarter. Chesley Taft & Associates LLC increased its holdings in shares of Eli Lilly and Company by 5.4% in the second quarter. Chesley Taft & Associates LLC now owns 22,553 shares of the company’s stock valued at $20,419,000 after purchasing an additional 1,163 shares in the last quarter. Finally, OMNI 360 Wealth Inc. bought a new position in Eli Lilly and Company in the 2nd quarter worth approximately $239,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.